<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407028</url>
  </required_header>
  <id_info>
    <org_study_id>GLR-NIH-2015</org_study_id>
    <nct_id>NCT02407028</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Brain Injury Treatment Trial</brief_title>
  <acronym>HOBIT</acronym>
  <official_title>Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hennepin Healthcare Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hennepin Healthcare Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this innovative adaptive phase II trial design is to determine the optimal
      combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate
      improvement in the outcome of severe TBI patients in a subsequent phase III trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical and clinical investigations strongly indicate that hyperbaric oxygen (HBO2) is
      physiologically active in improving the destructive processes in severe Traumatic Brain
      Injury (TBI). However, prior to a definitive efficacy study, important information is
      required regarding optimizing the HBO2 treatment paradigm instituted in terms of pressure and
      whether NBH enhances the clinical effectiveness of the HBO2 treatment. Preclinical
      investigators working with TBI models have used pressures varying from 1.5 to 3.0 atmospheres
      absolute (ATA). Clinical investigators have used pressure varying from 1.5 to 2.5 ATA.
      However, the lungs in severe TBI patients have frequently been compromised by direct lung
      injury and/or acquired ventilator pneumonia and are susceptible to oxygen (O2) toxicity.
      Working within these constraints, it is essential to determine the most effective HBO2
      treatment parameters without producing O2 toxicity and clinical complications. This proposed
      clinical trial is designed to answer these questions and to provide important data to plan a
      definitive efficacy trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow Outcome Scale Extended (GOS-E)</measure>
    <time_frame>Assessment at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ICP elevation</measure>
    <time_frame>First 5 days</time_frame>
    <description>The duration of ICP elevation will be measured using the area under the curve methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic intensity level scores for controlling intracranial pressure (ICP)</measure>
    <time_frame>First 5 days</time_frame>
    <description>This tracks the level of therapies used to control ICP during the first 5 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain tissue partial pressure of oxygen</measure>
    <time_frame>First 5 days</time_frame>
    <description>This outcome will be measured only in patients with LICOX monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>180 days</time_frame>
    <description>Events resulting in death, a life-threatening adverse event, or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak brain tissue oxygen (P02) during HBO treatments</measure>
    <time_frame>First 5 days</time_frame>
    <description>To examine the association between peak brain tissue PO2 during hyperbaric treatment and favorable outcome at 6-months (measured by the GOS-E).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA, no NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA, no NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA, no NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA + NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA + NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA + NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normobaric Hyperoxia (NBH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care for severe TBI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (1.5 ATA, no NBH)</intervention_name>
    <description>HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA, no NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.0 ATA, no NBH)</intervention_name>
    <description>HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA, no NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.5 ATA, no NBH)</intervention_name>
    <description>HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA, no NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (1.5 ATA + NBH)</intervention_name>
    <description>HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (1.5 ATA + NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.0 ATA + NBH)</intervention_name>
    <description>HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.0 ATA + NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric oxygen (2.5 ATA + NBH)</intervention_name>
    <description>HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead</description>
    <arm_group_label>Hyperbaric oxygen (2.5 ATA + NBH)</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normobaric Hyperoxia (NBH)</intervention_name>
    <description>100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead</description>
    <arm_group_label>Normobaric Hyperoxia (NBH)</arm_group_label>
    <other_name>NBH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Will be treated with usual and customary care for severe traumatic brain injury</description>
    <arm_group_label>Usual care</arm_group_label>
    <other_name>Standard of Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 16 years or older and 65 years or younger

          -  Present with severe TBI, defined as Glasgow Coma Scale (GCS) of 3 to 8.

          -  Marshall computerized tomography (CT) score &gt;1 in patients with a GCS of 7 or 8 or
             patients with an alcohol level &gt;200 mg/dl

          -  Ability to initiate the first hyperbaric oxygen treatment within 8 hours of admission
             in patients not requiring a craniotomy/craniectomy or any other major surgical
             procedure OR

          -  Ability to initiate the first hyperbaric oxygen treatment within 14 hours of admission
             in patients requiring a craniotomy/craniectomy or major surgical procedure

        Exclusion Criteria:

          -  First hyperbaric oxygen treatment cannot be initiated within 24 hours of injury

          -  GCS of 3 with mid-position and non-reactive pupils bilaterally (4mm)

          -  Penetrating head injury

          -  Pregnant

          -  Pre-existing neurologic disease (e.g. TBI or stroke or neurodegenerative disorder)
             with confounding residual neurologic deficits

          -  Unstable acute spinal cord injury

          -  Fixed coagulopathy

          -  Severe hypoxia

          -  Cardiopulmonary resuscitation performed

          -  Coma suspected to de due to primarily non-TBI causes

          -  Any contraindications to the study intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaylan L Rockswold, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Barsan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byron Gajewski, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick K Korley, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaylan L. Rockswold, M.D., Ph.D.</last_name>
    <phone>612-873-2810</phone>
    <email>gaylan.rockswold@hcmed.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Osborn Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lewandowski</last_name>
      <email>karen.lewandowski@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center - Hillcrest Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Curry</last_name>
      <email>tcurry@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magdolna Pakcos</last_name>
      <email>magdolna.pakocs@tenethealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Fairfield</last_name>
      <email>catherine-fairfield@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann Short</last_name>
      <email>joann.short@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Sult</last_name>
      <email>lsult@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhan Ayaz</last_name>
      <email>sfayaz@med.wayne.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals Butterworth Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristin Sternhagen</last_name>
      <email>Kristin.Sternhagen@spectrumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hennepin County Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jation</last_name>
      <email>jaton002@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Tom Bergman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmalee Metzler</last_name>
      <email>emmalee.metzler@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Herren</last_name>
      <email>luke.herren@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Thammavong</last_name>
      <email>jon.thammavong@bswhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Heath Services</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Carroll</last_name>
      <email>carpaul@hhsc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

